A gene therapy showing increased GCase activity, a biomarker-driven trial repurposing low-dose lithium, and new evidence linking oral bacteria to neuroinflammation. We also explore a fresh model of Lewy body formation centered on dysfunctional protein interactions rather than simple aggregation, alongside a human story that captures the long, realistic path
A “living drug” that makes L-DOPA in the gut moves toward human trials, gene therapies inch closer to the clinic, and new devices promise more precise brain targeting with less damage. Early-stage data also boost confidence in mitochondria-focused and GLP-1–based approaches. The brief Fresh sparks from the world of
Three new drugs showing real promise (apathy, falls, dyskinesia), HER-096 hits the brain safely and tees up a potential disease-modifier, and a fresh paper hints at a new metabolic target (TAL1). Plus: meet Jules King, proof that grit can rewrite the script. The brief Fresh sparks from the world of
Environmental factors like temperature, humidity, and altitude can worsen Parkinson’s symptoms, while new science points to surprising ways the environment might also help, from mild hypoxia protecting brain cells to cold exposure easing tremors. Meanwhile, a new dopamine drug (tavapadon) is nearing FDA approval, photobiomodulation shows promise, and Professor
New ways to understand Parkinson’s are emerging. Scientists finally saw the tiny protein clumps behind the disease, while other studies point to benefits from caffeine, less toxin exposure, and tracking stress. Plus some interesting data on neuromodulation. The brief Fresh sparks from the world of Parkinson’s: * For the
The UK launches its largest-ever trial (ACT-PD), stem-cell therapies show real recovery signs, and a new drug (HER-096) moves closer to testing brain protection. A paper exploring mild hypoxia as therapy and today’s tip: start your morning with gentle stretches. The brief Fresh sparks from the world of Parkinson’